Navigation Links
Andrew Powell Joins InterMune As Executive Vice President And General Counsel
Date:9/24/2013

BRISBANE, Calif., Sept. 24, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Andrew Powell has joined InterMune as Executive Vice President, General Counsel and Corporate Secretary.

(Logo:  http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

Mr. Powell will be responsible for managing the company's legal affairs.  He will report to Dan Welch, Chairman, Chief Executive Officer and President of InterMune.

Mr. Welch said, "Andrew brings experience in many areas that are key to InterMune's future as our Esbriet sales continue to grow globally, and we plan for anticipated approval and launch of Esbriet in the United States."

Mr. Powell's experience spans two decades of leadership in the life sciences, most recently as Executive Vice President, General Counsel and Secretary at Cornerstone Therapeutics. Mr. Powell has practiced law for more than 25 years, principally in healthcare and biotechnology.  He held positions of increasing responsibility for more than 15 years at the multi-national healthcare company Baxter, where he was instrumental in a series of transactions that established Baxter throughout Asia; Mr. Powell led the global law practice at Baxter Bioscience. Subsequently, he was part of the senior team that repositioned Collagenex Pharmaceuticals as a leader in dermatology.  Mr. Powell then served as SVP and General Counsel at ImClone Systems, where he helped the company grow before playing a key role in a successful process that resulted in a sale to Eli Lilly.

Mr. Powell holds a B.A. from the University of North Carolina at Chapel Hill and a J.D. from Stanford Law School.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved  for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com/.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
2. Eppendorf Video Features Dr Andrew Holts Work on Bioactive Leachates From Plastic Consumables
3. Green Dot Holdings LLC CEO, Mark Remmert, Joins Industry Thought Leaders to Discuss Holistic Sustainable Design at A Better World by Design Conference
4. Robert Tungatt, Regulatory Compliance and Cold Chain Excellence Specialist Joins QuickSTAT
5. Chinese Leader in Genomics Joins Science Center's Port Community
6. Greg Plum Joins the SoundConnect Team
7. Former Life Technologies and BD Biosciences Executive John L. "Kip" Miller Joins Solulinks Board of Directors
8. Dik Barsamian Joins the US HealthConnect Inc. Group of Companies as the New President of Its CME Enterprises
9. Denis Connaghan Joins Clinverse, Inc. as Chief Executive Officer
10. Jeffrey Toobin Joins Gateway Public Schools for the 2013 Matters of the Mind Luncheon
11. Former Head of UK Medicines & Healthcare Products Regulatory Agency (MHRA) Sir Alasdair Breckenridge Joins NDA Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... just published their findings on what they believe could be a new and ... of the new research. Click here to read it now. , ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight Medical ... to the healthcare market. The company's primary focus is on new product introductions, ... strategies that are necessary to help companies efficiently bring their products to market. ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):